235 related articles for article (PubMed ID: 18548231)
1. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
Gyertyán I; Sághy K; Laszy J; Elekes O; Kedves R; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Agai Csongor E; Domány G; Kiss B; Szombathelyi Z
Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):529-39. PubMed ID: 18548231
[TBL] [Abstract][Full Text] [Related]
2. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z
Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
[TBL] [Abstract][Full Text] [Related]
3. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
4. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
[TBL] [Abstract][Full Text] [Related]
5. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110.
Park WK; Jeong D; Yun CW; Lee S; Cho H; Kim GD; Koh HY; Pae AN; Cho YS; Choi KI; Jung JY; Jung SH; Kong JY
Pharmacol Res; 2003 Dec; 48(6):615-22. PubMed ID: 14527827
[TBL] [Abstract][Full Text] [Related]
7. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats.
Millan MJ; Gressier H; Brocco M
Eur J Pharmacol; 1997 Mar; 321(3):R7-9. PubMed ID: 9085054
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
9. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
Gyertyán I; Kiss B; Sághy K; Laszy J; Szabó G; Szabados T; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Csongor EÁ; Domány G; Tihanyi K; Szombathelyi Z
Neurochem Int; 2011 Nov; 59(6):925-35. PubMed ID: 21767587
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
Macdonald GJ; Branch CL; Hadley MS; Johnson CN; Nash DJ; Smith AB; Stemp G; Thewlis KM; Vong AK; Austin NE; Jeffrey P; Winborn KY; Boyfield I; Hagan JJ; Middlemiss DN; Reavill C; Riley GJ; Watson JM; Wood M; Parker SG; Ashby CR
J Med Chem; 2003 Nov; 46(23):4952-64. PubMed ID: 14584946
[TBL] [Abstract][Full Text] [Related]
11. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
12. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
13. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
Leucht S
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
[TBL] [Abstract][Full Text] [Related]
14. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
[TBL] [Abstract][Full Text] [Related]
15. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
16. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
17. Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning.
Li M; Sun T; Zhang C; Hu G
Psychopharmacology (Berl); 2010 Sep; 212(1):45-57. PubMed ID: 20623111
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride: from animal pharmacology to therapeutic action.
Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
Banasikowski TJ; Beninger RJ
Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
